Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

C-TIL051 · NKTR-255

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at Tumor neoantigens (patient tumor antigens) · developed by Nektar Therapeutics

Phase 1 Most advanced trial (none active)
NKTR Developer
1 Registered trials

What is C-TIL051?

C-TIL051 is a preparation of autologous tumor-infiltrating lymphocytes derived from each patient's resected tumor and expanded ex vivo. After administration back into the patient, the cells recognize and kill the patient's tumor cells. It is studied in metastatic non-small cell lung cancer, in combination with IL-15 (NKTR-255) and pembrolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NKTR-255, Pembrolizumab
Drug type
Cell therapy (Tumor-infiltrating lymphocytes)
Targets
Tumor neoantigens (patient tumor antigens) (antigen)
Mechanism
Kills target cells, directed at Tumor neoantigens (patient tumor antigens)
Therapy area
Oncology
Developer
Nektar Therapeutics (NKTR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
K25K2Y6N8C

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05676749 Phase 1 Metastatic Non Small Cell Lung Cancer Terminated NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Non Small Cell Lung Cancer

More from Nektar Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.

Follow NKTR, the company behind C-TIL051

See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.